<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04974567</url>
  </required_header>
  <id_info>
    <org_study_id>IRB # 21-0026</org_study_id>
    <nct_id>NCT04974567</nct_id>
  </id_info>
  <brief_title>Tear Based Sample Collection Breast Cancer Detection</brief_title>
  <official_title>Tear Based Sample Collection for Breast Cancer Detection</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Namida Lab</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>The University of Texas Medical Branch, Galveston</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Namida Lab</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study aims to collect tear samples from 50 women who have been recently diagnosed with&#xD;
      breast cancer.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Namida Lab, Inc. is a biotechnology company located in Fayetteville, AR, with a certified,&#xD;
      high-complexity CLIA lab. In January of 2021, Namida Lab, Inc. completed the analytical and&#xD;
      clinical validation of Melody®, a screening test for breast cancer based on proteins from&#xD;
      tears. The validation process was carried out manually and now needs to be conducted on the&#xD;
      Hamilton StarPlus automated ELISA system. To complete the robot validation, Namida Lab, Inc.&#xD;
      needs fifty (50) tear samples collected from women recently diagnosed with breast cancer but&#xD;
      who have not undergone any treatment.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Active, not recruiting</overall_status>
  <start_date type="Actual">April 28, 2021</start_date>
  <completion_date type="Anticipated">September 15, 2021</completion_date>
  <primary_completion_date type="Anticipated">August 31, 2021</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Number of participant tear samples collected.</measure>
    <time_frame>90 days</time_frame>
    <description>The purpose of this study is to collect 50 tear samples from women who have been recently diagnosed with breast cancer.</description>
  </primary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Actual">50</enrollment>
  <condition>Breast Cancer</condition>
  <condition>Tear</condition>
  <condition>Breast Cancer Female</condition>
  <arm_group>
    <arm_group_label>Women recently diagnosed with breast cancer who have not undergone any treatment.</arm_group_label>
    <description>Tear sample collection</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Melody®</intervention_name>
    <description>Melody® is a tear-based screening assay for breast cancer developed and validated by Namida Lab, Inc., a high complexity CLIA certified lab. Melody® consists of two parts: tear sample collection and clinical lab test. Melody® is a high-complexity lab-developed test for breast cancer screening.</description>
    <arm_group_label>Women recently diagnosed with breast cancer who have not undergone any treatment.</arm_group_label>
  </intervention>
  <biospec_retention>Samples Without DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      Lacrimal (tear) fluid&#xD;
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        The Tear Based Breast Cancer Detection study participants are all women, born biologically&#xD;
        female, with a recent diagnosis of breast cancer, have not started treatment, and are&#xD;
        between the ages of 18 to 100 years old.&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Individual is an adult woman and has recently been diagnosed with breast cancer.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Individual is excluded if they have already started treatment for the breast cancer&#xD;
             diagnosis.&#xD;
&#xD;
          -  Age less than 18 or more than 100 years.&#xD;
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>100 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Suzanne Klimberg, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>UTMB Health</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>UTMB Health</name>
      <address>
        <city>Galveston</city>
        <state>Texas</state>
        <zip>77555-0737</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>July 2021</verification_date>
  <study_first_submitted>June 24, 2021</study_first_submitted>
  <study_first_submitted_qc>July 13, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">July 23, 2021</study_first_posted>
  <last_update_submitted>July 13, 2021</last_update_submitted>
  <last_update_submitted_qc>July 13, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">July 23, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>preventative screening</keyword>
  <keyword>protein biomarkers</keyword>
  <keyword>lacrimal tear fluid</keyword>
  <keyword>mammography</keyword>
  <keyword>ELISA assay</keyword>
  <keyword>CLIA laboratory</keyword>
  <keyword>lab developed test</keyword>
  <keyword>high complexity</keyword>
  <keyword>tear collection</keyword>
  <keyword>mammogram</keyword>
  <keyword>improved patient outcomes</keyword>
  <keyword>reduce gap in access</keyword>
  <keyword>health equity</keyword>
  <keyword>total cost of care</keyword>
  <keyword>trust from patient</keyword>
  <keyword>increased compliance</keyword>
  <keyword>affordable</keyword>
  <keyword>low cost</keyword>
  <keyword>non-invasive</keyword>
  <keyword>women's health and wellness</keyword>
  <keyword>breast health</keyword>
  <keyword>breast cancer screening test</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Breast Neoplasms</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
    <ipd_description>IPD will not be shared or made available to other researchers.</ipd_description>
  </patient_data>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>No</document_has_sap>
      <document_date>April 13, 2021</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/67/NCT04974567/Prot_000.pdf</document_url>
    </provided_document>
    <provided_document>
      <document_type>Informed Consent Form</document_type>
      <document_has_protocol>No</document_has_protocol>
      <document_has_icf>Yes</document_has_icf>
      <document_has_sap>No</document_has_sap>
      <document_date>April 28, 2021</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/67/NCT04974567/ICF_001.pdf</document_url>
    </provided_document>
  </provided_document_section>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

